Costanza FABBRI
(Scuola Superiore Sant'Anna - Istituto di Fisiologia clinica CNR Pisa)
13/03/26, 16:00
Background: Cancer theranostics integrates molecular imaging and targeted radionuclide therapy using matched radiopharmaceutical pairs with identical molecular scaffolds labeled with diagnostic radionuclides such as fluorine-18 or gallium-68, and therapeutic emitters such as lutetium-177 [1]. Recent advances have led to the clinical translation of selective radiotracers exploiting differential...
